Catalyst Pharmaceuticals Notified of Abbreviated New Drug Application Filing for FIRDAPSE®
23 janv. 2023 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing,...
Catalyst Pharmaceuticals to Acquire U.S. Commercial Rights to FYCOMPA® (Perampanel) CIII From Eisai Co., Ltd
19 déc. 2022 16h10 HE
|
Catalyst Pharmaceuticals, Inc.
Acquisition Expands The Company’s Commercial Portfolio With An Established U.S. Marketed Product Company Remains Dedicated To Growth Within Neurology Through Continued Active Business Development...
Catalyst Pharmaceuticals Reports Record Third Quarter 2022 Financial Results and Provides a Corporate Update
09 nov. 2022 16h11 HE
|
Catalyst Pharmaceuticals, Inc.
Achieved Record Q3 2022 FIRDAPSE® Net Revenue of $57.2 Million, a 59.3% YoY Increase Company Increases Full Year 2022 Total Revenue Guidance to $205-210 Million Q3 2022 GAAP Net Income of $22.7...
Catalyst Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 9, 2022
25 oct. 2022 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing,...
Catalyst Pharmaceuticals Reports Record First Quarter 2022 Financial Results And Provides Corporate Update
10 mai 2022 16h11 HE
|
Catalyst Pharmaceuticals, Inc.
Achieved Record Revenues of more than $43 Million, a 42.7% Increase YoY Three New Patents Issued; Now Five Orange-Book Listed Patents for FIRDAPSE® Significant Cash Position of $198 Million and...
Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
16 mars 2022 16h21 HE
|
Catalyst Pharmaceuticals, Inc.
Total 2021 Revenues Increased Approximately 18% YoY to $141 Million Strong 2022 Revenue Growth Expected, Supported by FIRDAPSE® Orphan Drug Exclusivity New Patent Issuances Strengthens FIRDAPSE...
Catalyst Pharmaceuticals and KYE Pharmaceuticals Announce a Second Favorable Canadian Federal Court Ruling Setting Aside Approval of Ruzurgi®
11 mars 2022 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., March 11, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...
Catalyst Pharmaceuticals Named Among Forbes 2022 America's Best Small Companies
08 mars 2022 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., March 08, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...
Catalyst Pharmaceuticals Teams Up with Patients and Advocacy Groups to Ring Nasdaq Opening Bell on Rare Disease Day 2022
24 févr. 2022 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
Ceremony Recognizes Importance of Biopharma Industry and Advocacy Group Collaboration to Address Needs for New Treatments in Orphan and Rare Disorders Together, Will Ring the Nasdaq Opening Bell to...
Catalyst Pharmaceuticals to Launch LEMS Aware Podcast on Rare Disease Day 2022
17 févr. 2022 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on developing...